Indication:
Ovarian Cancer: Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.
Multiple Myeloma: The product, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.
AIDS-Related Kaposi's Sarcoma: Treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.
Strength:20mg:10ml; 50mg:25ml
Innovator: Janssen-Cilag International NV /Baxter Holding B.V.
Innovative Brand: Caelyx /Caelyx Pegylated Liposomal
Has passed Consistency Evaluation
（2022.01）
Qualification: Approved in China. European  RLD. Under registration to Central America
Key selling points: 
1. Liposomal formulations can mitigate cardiac toxicity, bone marrow suppression, and alopecia, among other side effects, thereby enhancing patients' tolerability and quality of life.
2. With a broad clinical application range, Doxorubicin Hydrochloride Liposome Injection have been extensively utilized in treating various cancers, including Kaposi's sarcoma, multiple myeloma, breast cancer, and ovarian cancer.